ADVM Jul 2024 8.000 call
| Previous Close | 0.3500 |
| Open | 0.3500 |
| Bid | 0.2000 |
| Ask | 0.4500 |
| Strike | 8.00 |
| Expire Date | 2024-07-19 |
| Day's Range | 0.3500 - 0.3500 |
| Contract Range | N/A |
| Volume | |
| Open Interest | 6 |
GlobeNewswireAdverum Biotechnologies to Participate in TD Cowen’s Genetic Medicines & RNA Summit
REDWOOD CITY, Calif., June 18, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company pioneering the use of gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that Laurent Fischer, M.D., president and chief executive officer of Adverum Biotechnologies, will participate in a fireside chat at TD Cowen’s Genetic Medicines & RNA Summit on Friday, June 21, 2024 at 10:00 a.m. ET. The webcast of the presentation may be a
- GlobeNewswire
Adverum Biotechnologies Announces Appointments of Dr. Rabia Gurses Ozden as Chief Medical Officer and Dr. Szilárd Kiss as a Member of the Board of Directors
REDWOOD CITY, Calif., June 11, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company pioneering the use of gene therapy as a new standard of care for highly prevalent ocular diseases, today announced the appointments of Dr. Rabia Gurses Ozden to the Company’s executive leadership team as chief medical officer and Dr. Szilárd Kiss to the Company’s Board of Directors. Dr. Ozden has stepped down from the Company’s Board of Directors, with Dr. Kiss filling t
- GuruFocus.com
Adverum Biotechnologies Reports Q1 2024 Results: A Detailed Look at Financials and Pipeline Progress
Insight into Adverum's First Quarter Financial Performance and Future Prospects
